Monday, October 7, 2013
• Curis Inc., of Lexington, Mass., said partner Roche AG, of Basel, Switzerland, began a Phase Ib/II study with Erivedge (vismodegib) in patients with relapsed/ refractory acute myelogenous leukemia and relapsed/refractory high-risk myelodysplastic syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.